Anthony Baldor, MS, MBA, Chief Financial Officer & Head of Business Development • 20 years in oncology, immunology and rare disease with career focus on strategy, finance and business development • 40+ transactions ($2.5B+) spanning the biopharma company life cycle from formation to acquisition, including academic licensing, venture capital, public financings, pharma partnerships and M&A Anthony brings deep and balanced biotech experience to the team. His unique career builds off early scientific training at oncology and immunology research laboratories in both Boston (Harvard Medical School, Dana Farber, Broad Institute) and in Cambridge (Cequent Pharma). With this strong technical foundation, Anthony transitioned into business development and finance where he quickly developed a deal record of over 40 transactions including 10 venture financings (RMI Partners, BioInnovation Capital), 9 IPOs (Jefferies, 4DMT) and 3 biopharma deals (ViThera, 4DMT). Anthony comes to Diakonos from 4DMT where he was Vice President of Corporate Strategy and Development, taking hands-on leadership roles for the Series C, IPO, Astellas partnership and Aevitas acquisition. Anthony thrives on dynamic teams in small organizations – in addition to these core career experiences, saying “yes” has earned him interim leadership roles in PR, IR and alliance management.